| Down patients with Eisenmenger syndrome: is bosentan treatment an option? | |
| | |
MedLine Citation:
|
PMID: 18579234 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Favorable results of treatment with bosentan in patients with Eisenmenger syndrome are available. However, data in Down patients are lacking. In this study, we evaluate the therapeutic role of bosentan treatment in Down patients with Eisenmenger syndrome. METHODS: In this open-label study, 24 Down patients (>18 years) with Eisenmenger syndrome (17 males) were treated with bosentan. Their mean age was 38 years (range 19-55 years). All Down patients were evaluated at baseline and during follow-up with laboratory tests, six-minute walk test (6-MWT), Doppler echocardiography, and quality of life questionnaires. RESULTS: The median follow-up of Down patients treated with bosentan was 11.5 months (range 3-23 months). Induction of oral bosentan therapy was well tolerated among all 24 Down patients. Bosentan treatment was generally well tolerated. No serious adverse drug reactions were noted. Median 6-MWT increased from 296 m (range 40-424 m) to 325 m (range 84-459 m, p<0.05) after 12 weeks. After 26 and 52 weeks of treatment with bosentan, median 6-MWT distance was 276 m (range 140-462 m, n=15, p=0.6) and 287 m (range 131-409 m, n=7, p=0.3), respectively. Quality of life questionnaire scores remained stable during treatment. CONCLUSION: Also patients with Down syndrome may benefit from bosentan treatment when they have Eisenmenger syndrome. Medical treatment appears to be safe and the treatment effects do not deviate from those observed in Eisenmenger patients without Down syndrome. |
| | |
Authors:
|
Mari?lle G J Duffels; Jeroen C Vis; Rosa L E van Loon; Rolf M F Berger; Elke S Hoendermis; Arie P J van Dijk; Berto J Bouma; Barbara J M Mulder |
Related Documents
:
|
6406594 - High incidence of free monoclonal lambda light chains in the sera of patients with sjog... 15283784 - Epidermal nevus syndromes: clinical findings in 35 patients. 3025464 - Alpha 2-adrenergic receptor levels in obstructive and spastic raynaud's syndrome. 19860524 - Craniofacial morphology in patients with velocardiofacial syndrome. 12363104 - Fanconi syndrome caused by sodium valproate: report of three severely disabled children. 21766054 - The cachexia score (casco): a new tool for staging cachectic cancer patients. |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2008-06-24 |
Journal Detail:
|
Title: International journal of cardiology Volume: 134 ISSN: 1874-1754 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-05-11 Completed Date: 2010-02-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 378-83 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Down Syndrome / complications*, drug therapy*, physiopathology Eisenmenger Complex / complications*, drug therapy*, physiopathology Female Follow-Up Studies Humans Male Middle Aged Sulfonamides / therapeutic use* Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Sulfonamides; 147536-97-8/bosentan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Levosimendan may provide a better neurohormonal response in heart failure patients receiving beta bl...
Next Document: Pheochromocytoma crisis presenting with shock and tako-tsubo-like cardiomyopathy.